Search results
Nanobiotix S.A. to Post FY2025 Earnings of $1.07 Per Share, Leerink Partnrs Forecasts (NASDAQ:NBTX)
ETF DAILY NEWS· 17 hours agoNanobiotix S.A. (NASDAQ:NBTX – Free Report) – Leerink Partnrs raised their FY2025 earnings per share (EPS) estimates for Nanobiotix in a research note issued on Thursday, April 25th. Leerink ...
Mercy BioAnalytics to Present Results from a Large Ovarian Cancer Screening Study at the ASCO Annual...
Denton Record-Chronicle· 5 days agoMercy BioAnalytics, Inc., a pioneer in extracellular vesicle-based liquid biopsy for the early detection of cancer, will present data at the 2024 American Society of Clinical ...
Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting
Morningstar· 4 days agoCandel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight ...
Mercy BioAnalytics to Present Results from a Large Ovarian Cancer Screening Study at the ASCO Annual...
The Longview News-Journal· 5 days agoMercy BioAnalytics, Inc., a pioneer in extracellular vesicle-based liquid biopsy for the early detection of cancer, will present data at the 2024 American Society of Clinical ...
Mercy BioAnalytics to Present Results from a Large Ovarian Cancer Screening Study at the ASCO Annual...
Newswise· 6 days agoWALTHAM, Mass., April 24, 2024 /PRNewswire/ -- Mercy BioAnalytics, Inc., a pioneer in extracellular vesicle-based liquid biopsy for the early detection of cancer, will present ...
Prairie Fare: Are you taking care of your skin?
The Bismarck Tribune· 5 days ago“I thought you were wearing white knee socks,” someone said.
BioNTech (BNTX) to Release Earnings on Monday
ETF DAILY NEWS· 17 hours agoBioNTech (NASDAQ:BNTX – Get Free Report) is scheduled to be posting its quarterly earnings results before the market opens on Monday, May 6th. Analysts expect BioNTech to post earnings of ($0.45 ...
MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation...
Digital Journal· 5 days agoThe primary objectives of the trial include determining the maximum tolerated dose and/or recommended Phase 2 dose and evaluating antitumor activity of tulmimetostat monotherapy. The safety ...
Foresee Pharmaceuticals Announces Poster Presentation and Participation at the 2024 American...
WTNH-TV New Haven· 13 hours agoForesee Pharmaceuticals (TPEx: 6576) ("Foresee") announced today that it will actively participate...
3 Defensive Stocks to Protect Your Portfolio in 2024 | Investing.com
Investing.com· 6 days agoAfter the Iran-Israel situation fizzled out for the time being, the Cboe Volatility Index (VIX)...
